<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3664">
  <stage>Registered</stage>
  <submitdate>16/10/2012</submitdate>
  <approvaldate>16/10/2012</approvaldate>
  <nctid>NCT01711125</nctid>
  <trial_identification>
    <studytitle>Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease</studytitle>
    <scientifictitle>Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease</scientifictitle>
    <utrn />
    <trialacronym>BacALD</trialacronym>
    <secondaryid>X11-0154</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alcoholic Liver Disease</healthcondition>
    <healthcondition>Alcohol Dependence</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Liver</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Baclofen 30mg/day
Treatment: drugs - Baclofen 75mg/day
Treatment: drugs - Placebo

Experimental: Arm 1 - Baclofen low dose

Experimental: Arm 2 - Baclofen high dose

Placebo Comparator: Arm 3 - Placebo


Treatment: drugs: Baclofen 30mg/day
30mg/day 10 mg t.i.d

Treatment: drugs: Baclofen 75mg/day
75mg/day 25 mg t.i.d

Treatment: drugs: Placebo
Placebo 3 matched tabs/day

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>alcohol consumption - as measured by the number of days abstinent, number of heavy drinking days, time to relapse, time to lapse and number of drinks per drinking day</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>clinical markers of liver injury</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>incidence of hepatic side effects</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>craving for alcohol</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>early termination due to side effects</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  ALD (for trial group 1), defined as the presence of symptoms and/or signs referable to
             liver disease with or without cirrhosis, in which alcohol use is considered to play a
             major aetiological role. Alcohol use will have exceeded an average of 60g/day in women
             and 80g/day in men for &gt;10 years.

          -  Alcohol dependence according to the ICD-10 criteria (for both trial 1 and 2)

          -  Adequate cognition and English language skills to give valid consent and complete
             research interviews

          -  Willingness to give written informed consent

          -  Abstinence from alcohol for between 3 and 21 days

          -  Resolution of any clinically evident alcohol withdrawal (CIWA-AR)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Active major psychological disorder associated with psychosis or significant suicide
             risk

          -  Pregnancy or lactation

          -  Concurrent use of any psychotropic medication other than antidepressants

          -  Substance use other than nicotine if unstable

          -  Clinical evidence of persisting hepatic encephalopathy

          -  Pending incarceration

          -  Lack of stable housing

          -  Active peptic ulcers

          -  Unstable diabetes mellitus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>104</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2017</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Drug Health Services, Royal Prince Alfred Hospital - Sydney</hospital>
    <postcode>2050 - Sydney</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>South West Sydney Local Health District</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Sydney</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To explore the effectiveness and biobehavioural basis of baclofen in improving treatment
      outcomes for alcohol dependence in people with or without alcoholic cirrhosis in a
      double-blind randomised placebo-controlled trial.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01711125</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul S Haber, MBBS</name>
      <address>Sydney Local Health District</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>